AbstractHIV DNA is a marker of HIV persistence that predicts HIV progression and remission, but its kinetics in early acute HIV infection (AHI) is poorly understood. We longitudinally measured the frequency of peripheral blood mononuclear cells harboring total and integrated HIV DNA in 19 untreated and 71 treated AHI participants, for whom 50 were in the earliest Fiebig I/II (HIV IgM−) stage, that is ≤2weeks from infection. Without antiretroviral therapy (ART), HIV DNA peaked at 2weeks after enrollment, reaching a set-point 2weeks later with little change thereafter. There was a marked divergence of HIV DNA values between the untreated and treated groups that occurred within the first 2weeks of ART and increased with time. ART reduced total...
Residual viremia is common during antiretroviral therapy (ART) and could be caused by ongoing low-le...
International audienceBACKGROUND:In the current context of research on HIV reservoirs, offering new ...
Despite prolonged treatment with highly active antiretroviral therapy (HAART), the infectious HIV-1 ...
HIV DNA is a marker of HIV persistence that predicts HIV progression and remission, but its kinetics...
AbstractHIV DNA is a marker of HIV persistence that predicts HIV progression and remission, but its ...
In HIV-1 infection, a population of latently infected cells facilitates viral persistence despite an...
In HIV-1 infection, a population of latently infected cells facilitates viral persistence despite an...
In HIV-1 infection, a population of latently infected cells facilitates viral persistence despite an...
Background: Understanding factors affecting the size and the evolution of the HIV reservoir is essen...
Abstract Background Viral reservoir size refers to cellular human immunodeficiency virus-1 (HIV-1) D...
In HIV-1 infection, a population of latently infected cells facilitates viral persistence despite an...
BACKGROUND: Despite prolonged treatment with highly active antiretroviral therapy (HAART), the infec...
Cellular human immunodeficiency virus type 1 (HIV-1) DNA may be considered a marker of disease progr...
Background: Few data have been reported on the dynamics of HIV-1 DNA during intermittent highly acti...
Residual viremia is common during antiretroviral therapy (ART) and could be caused by ongoing low-le...
Residual viremia is common during antiretroviral therapy (ART) and could be caused by ongoing low-le...
International audienceBACKGROUND:In the current context of research on HIV reservoirs, offering new ...
Despite prolonged treatment with highly active antiretroviral therapy (HAART), the infectious HIV-1 ...
HIV DNA is a marker of HIV persistence that predicts HIV progression and remission, but its kinetics...
AbstractHIV DNA is a marker of HIV persistence that predicts HIV progression and remission, but its ...
In HIV-1 infection, a population of latently infected cells facilitates viral persistence despite an...
In HIV-1 infection, a population of latently infected cells facilitates viral persistence despite an...
In HIV-1 infection, a population of latently infected cells facilitates viral persistence despite an...
Background: Understanding factors affecting the size and the evolution of the HIV reservoir is essen...
Abstract Background Viral reservoir size refers to cellular human immunodeficiency virus-1 (HIV-1) D...
In HIV-1 infection, a population of latently infected cells facilitates viral persistence despite an...
BACKGROUND: Despite prolonged treatment with highly active antiretroviral therapy (HAART), the infec...
Cellular human immunodeficiency virus type 1 (HIV-1) DNA may be considered a marker of disease progr...
Background: Few data have been reported on the dynamics of HIV-1 DNA during intermittent highly acti...
Residual viremia is common during antiretroviral therapy (ART) and could be caused by ongoing low-le...
Residual viremia is common during antiretroviral therapy (ART) and could be caused by ongoing low-le...
International audienceBACKGROUND:In the current context of research on HIV reservoirs, offering new ...
Despite prolonged treatment with highly active antiretroviral therapy (HAART), the infectious HIV-1 ...